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Background. Increased intestinal permeability may be one of the mechanisms of transmission of human immu-
nodeficiency virus (HIV) to infants through breast-feeding. Intestinal permeability correlates with microbial translo-
cation, which can be measured through quantification of bacterial lipopolysaccharide (LPS).
Methods. We evaluated levels of plasma LPS (by the Limulus amebocyte lysate assay) and immune activation
markers in serial specimens from infants exposed to but uninfected with HIV and infants infected with HIV from
the Breastfeeding, Antiretrovirals, and Nutrition (BAN) study.
Results. Plasma LPS levels increased after infants in the BAN study were weaned from the breast, at 24 weeks of
age. Cotrimoxazole prophylaxis was associated with higher plasma LPS levels (P = .004). Infants with HIV infection
had higher LPS levels, compared with uninfected infants (P = .004). Higher preinfection plasma LPS levels were a
significant predictor of infant HIV infection through breast-feeding (hazard ratio = 1.60 for every unit increase in
plasma LPS level; P = .01) and of lower infant length-for-age z scores (P = .02).
Conclusions. These findings suggest that disruption in intestinal integrity is a mechanism of HIV transmission
to infants through breast-feeding. Weaning from breast milk and use of antibiotic prophylaxis was associated with
increased levels of microbial translocation, which could facilitate HIV entry through the intestine. Complementary
approaches to enhance intestinal mucosal integrity in the infant may further reduce breast-feeding transmission of
HIV.
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The majority of breast-fed infants of mothers infected
with human immunodeficiency virus type 1 (HIV)
remain uninfected despite ingesting liters of HIV-
containing breast milk over several months [1]. The
mechanisms of protection from infection and transmis-
sion are incompletely understood. In particular, much
remains to be learned about the role of mucosal barri-
ers and the innate and adaptive immune responses
that defend infants against mucosal HIV transmission.
Increased intestinal permeabilitymay be one of themech-
anisms facilitating HIV transmission through breast-
feeding. In young infants, as the intestinal barrier
matures, the tight junctions between enterocytes close
and intestinal permeability decreases [2]. Gastrointesti-
nal infections and malnutrition disrupt this maturation-
al process and increase intestinal permeability, as does
artificial (ie, formula) feeding [3]. This mechanism may
account for the higher risk of HIV infection with mixed
feeding, compared with exclusive breast-feeding [4]. A
study showed that African infants displayed increasing
intestinal permeability after 3 months of life, contrary
to European infants, and by 12 months of life intestinal
permeability was 5 times as high in African infants,
compared with European infants [5]. Traditionally, as-
says to evaluate intestinal permeability have been based
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on differential absorption of carbohydrates (such as the lactu-
lose-mannitol assay) [3, 5]. Such assays are cumbersome and
time intensive, particularly for infants.
The intestinal epithelium acts as a barrier to luminal con-
tents, including bacteria and endotoxins. Injuries to the intesti-
nal barrier result in bacterial or endotoxin translocation from
the intestinal lumen to the systemic circulation through the in-
testinal mucosa, in the absence of overt bacteremia [6]. This
process is termed microbial translocation, and it can be quanti-
fied by measuring plasma levels of lipopolysaccharide (LPS), an
endotoxin and component of gram-negative bacteria [6–8]. In-
testinal permeability, measured by the lactulose-mannitol test,
and systemic endotoxemia, measured by detection of LPS by
the Limulus amebocyte lysate assay, showed a significant posi-
tive correlation in one study [6]. Elevated plasma LPS levels are
indicative of disrupted intestinal mucosal integrity and can
occur after invasive gastrointestinal surgery, in graft-versus-
host disease, and in inflammatory bowel disease, as well as in
HIV infection [6, 9–11]. LPS is a potent stimulator of macro-
phages, monocytes, and neutrophils and causes release of cyto-
kines that are inflammatory mediators [11, 12].
We postulated that microbial translocation through the gut,
a marker of disrupted intestinal mucosal integrity, may corre-
late with increased risk of acquisition of HIV infection through
breast-feeding. We tested this hypothesis with samples from
the Breastfeeding, Antiretrovirals, and Nutrition (BAN) study,
a large prospectively followed cohort of breast-fed infants born
to HIV-infected mothers. We studied plasma LPS levels and
cellular and soluble markers of immune activation at various
times during infants’ first year of life to determine the dynamics
of microbial translocation through the gut and examine its rela-
tionship with feeding pattern (ie, breast-feeding vs weaned
status), receipt of antibiotic prophylaxis, and infants’ nutrition-
al status; to explore the correlation of microbial translocation
with cellular and soluble markers of immune activation; and to
determine the role of microbial translocation in acquisition of
HIV infection through breast-feeding.
METHODS
BAN Study Design and Subjects
All infants were enrolled in the BAN randomized, controlled
trial, which has been described elsewhere [13]. Briefly, pregnant
HIV-infected women with CD4+ T cell counts >250 cells/μL
(≥200 cells/μL before 24 July 2006; the change accords with
Malawi Ministry of Health guidelines) were enrolled and fol-
lowed in Lilongwe, Malawi, from April 2004 to January 2010.
All women provided written informed consent. The study pro-
tocol was approved by the Malawi National Health Science Re-
search Committee and by institutional review boards at the
University of North Carolina and the Centers for Disease
Control and Prevention.
Mother-infant pairs were randomly assigned within 1 week
of birth to a 2-group maternal nutritional intervention and to a
3-group antiretroviral intervention consisting of a triple-drug
antiretroviral regimen for mothers (n = 849), daily nevirapine
for infants (n = 852), or neither (control arm; n = 668). Irre-
spective of antiretroviral treatment assignment, all mothers in
labor and their newborns were given a single dose of nevirapine
and a 7-day course of zidovudine and lamivudine. The inter-
ventions began after delivery and were continued until breast-
feeding cessation but for no longer than 28 weeks. Infants
found to be HIV infected within the first 2 weeks of life were
disenrolled from the study and referred for care. All mothers
were counseled to breast-feed exclusively for the first 24 weeks
of life, followed by a 4-week weaning period; a locally produced
ready-to-use therapeutic food was provided as a weaning sup-
plement [13]. Self-reported compliance with study feeding
counseling was high—95% of mothers were breast-feeding at
24 weeks (88% were practicing exclusive breast-feeding)—but
infants for >90% had been weaned by 28 weeks [14].
Infants were tested for HIV infection at birth and at 2, 12,
28, and 48 weeks of age with the Roche Amplicor 1.5 DNA po-
lymerase chain reaction assay. HIV-infected infants were re-
ferred for care.
In accordance with the Malawi Ministry of Health and
World Health Organization (WHO) guidelines, cotrimoxazole
prophylaxis (240 mg once daily from 6 to 36 weeks of age or
until weaning and HIV infection was ruled out) was initiated in
infants in the BAN study in June 2006 [13]. Infant weight was
measured at 0, 24, 28, 32, 36, 42, and 48 weeks of age, using
Tanita digital infant scales (0.1-g increments), which were cali-
brated daily using a standard 1-kg weight. Recumbent length
was measured using length boards made to UNICEF (United
Nations Children’s Fund) specifications (0.1-cm increments).
Length-for-age and weight-for-age z scores were calculated
using the WHO growth standards [15].
Infants were selected for the current analysis on the basis of
the availability of serial samples of peripheral blood mononu-
clear cells (PBMCs) and plasma. The analysis included the 39
infants (19 males and 20 females) from the control arm who re-
mained HIV uninfected and had available samples at 4 (n = 18)
or 5 (n = 21) of the desired time points (birth, 12, 24, 36, and
48 weeks of age). The study also included a random sample of
30 infants (14 males and 16 females) who were determined to
be infected perinatally (defined on the basis of a positive HIV
DNA polymerase chain reaction test result within first 2 weeks
of life); all 30 were from the group of 41 infants with available
plasma and PBMCs at delivery. Twenty-six of the 30 perinatally
infected infants received a diagnosis during the first 2 days of
life and were thus considered to have acquired HIV in utero [16].
These infants provided samples only at the time of birth. In ad-
dition, 25 (17 males and 8 females) of the 93 BAN study infants
who became HIV infected during breast-feeding (ie, after 2
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weeks of life) and had plasma and PBMC specimens from at
least 2 of the prespecified time points before infection and 1 time
point after infection were included; 16 of these acquired HIV in-
fection in the first 6 months of life, and 9 acquired infection in
the second 6 months of life. These infants were from all BAN
study arms. For time points before HIV was detected, these
infants were considered HIV uninfected in the analyses. The
median time of mother-reported weaning for infants who were
HIV uninfected at 28 weeks of age was 24.6 weeks (interquartile
range, 24.0–28.0 weeks). Almost all infants who were HIV infect-
ed by 28 weeks continued to breast-feed until the end of study
follow-up, in accordance with current recommendations.
Cellular Markers
Lymphocyte immunophenotyping was performed as described
elsewhere [17]. Briefly, cryopreserved PBMCs were quickly
thawed, washed twice with complete medium (ie, Roswell Park
Memorial Institute 1640 medium, 10% fetal bovine serum,
penicillin/streptomycin, and L-glutamine), and resuspended at
5 × 106/mL in FACS buffer (phosphate-buffered saline contain-
ing 2% bovine serum albumin and 0.1% NaN3). An amount of
100 μL was stained at room temperature for 20 minutes and
then washed with FACS buffer before fixing in 300 μL of 1%
paraformaldehyde. The panel of markers used included the fol-
lowing: T-lymphocyte markers (CD3, CD4, and CD8), activa-
tion markers (CD38 and HLA-DR), and 7-AAD (for dead cell
exclusion). All monoclonal antibodies used were from BD Bio-
sciences (San Jose, CA). Acquisition of data and cell subset
analysis were performed with FACSCalibur (BD Biosciences),
using FlowJo software (Tree star).
Soluble Markers
Plasma LPS levels were quantified by the Limulus amebocyte
lysate assay QCL-1000, according to the manufacturer’s proto-
col (Cambrex Bioscience, Walkersville, MD). Briefly, samples
were diluted 1:10 with endotoxin-free water, heat-inactivated at
65°C for 10 minutes, vigorously mixed, and tested in 96-well
microplates according to the manufacturer’s instructions. The
optical densities (ODs) were converted into enzyme units (EU)
per milliliter on the basis of a standard curve.
Plasma concentrations of soluble CD14 (sCD14; R&D
Systems, Minneapolis, MN) and soluble L-selectin (sL-selectin;
R&D Systems, Minneapolis, MN) were tested in duplicate by
enzyme-linked immunosorbent assay per the manufacturer’s
specifications. The lower detection limits for LPS, sCD14,
and sL-selectin were 0.1 EU/mL, 125 pg/mL, and 300 pg/mL,
respectively.
Statistical Analysis
Results are reported as median values (interquartile ranges).
Analysis of variance was determined using the Mann-Whitney
U test. Spearman correlations (r and P values) were calculated
to determine the relationships between plasma LPS levels, sCD14
levels, sL-selectin levels, and cellular activation markers. Linear
mixed-effects models with an autoregressive covariance struc-
ture were used to evaluate the effect of infant age and HIV
status on plasma levels of LPS and cellular and soluble markers
and the effect of cotrimoxazole prophylaxis on plasma LPS
levels, after adjustment for maternal CD4+ T-cell count at base-
line and infant birth weight. Trends in plasma levels of LPS and
cellular and soluble immune activation markers over the first
year of life were assessed using nonparametric smoothing
splines. Linear mixed models adjusted for study arm, maternal
CD4+ T-cell count, time, infant birth weight, sex, and HIV
status were used to evaluate whether plasma levels of immune
markers were associated with z scores of infant weight-for-age
and length-for-age. The Cox proportional hazards model was
used to determine whether plasma levels were associated with
time to infant HIV infection, after control for study arm, mater-
nal CD4+ T-cell count, and birth weight.
RESULTS
Microbial Translocation and Immune Activation Increase
During the First Year of Life in Infants Infected With HIV and
Those Exposed to and Uninfected With HIV
Plasma LPS, a marker of microbial translocation, was detectable
in HIV-exposed but uninfected newborns, and levels remained
stable until 24 weeks of age. Small increases in median plasma
LPS levels were observed after the first 24 weeks of life in HIV-
uninfected infants, but levels seemed to stabilize between 36
and 48 weeks (Table 1 and Figure 1). Infants with HIV infec-
tion displayed higher LPS levels at the time of birth and rela-
tively stable levels until 36 weeks, with a subsequent increase at
48 weeks of age (Figure 1).
Plasma levels of sCD14, a marker of monocyte/macrophage
activation, significantly increased with age for both groups of
infants (P < .001; Figure 2). Increasing trends in sCD14 levels
were noted earlier than for LPS levels in both HIV-infected
infants and uninfected infants (Table 1 and Figures 1 and 2).
Plasma levels of sL-selectin, a marker of lymphocyte activation,
increased nonlinearly with age in both HIV-infected infants
and uninfected infants (P < .001). The increase in sL-selectin
level was most rapid very early in life, before weaning
(Figure 3). Levels of CD4+ and CD8+ T-lymphocyte activation,
measured by expression of the markers CD38 and HLA DR,
also had a trend of increasing over the first year of life in both
HIV-infected infants and uninfected infants (Table 1).
HIV-Infected Infants Have Higher Levels of Microbial
Translocation and Immune Activation Than Uninfected Infants
Overall, median plasma LPS levels were higher in HIV-infected
infants, compared with uninfected infants (P = .004 from a longi-
tudinal mixed model; data not shown; Figure 1). The differences
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were statistically significant even at birth: infants with HIV in-
fection detected in the first 2 days of life had a median LPS level
of 1.73 EU/mL, compared with 1.20 EU/mL in uninfected in-
fants (P = .006). At 48 weeks of age, HIV-infected infants also
had higher median plasma LPS levels, compared with uninfect-
ed infants (P = .04) (Table 1).
Plasma levels of sCD14 were also elevated in HIV-infected
infants, compared with uninfected infants (P = .002 from a lon-
gitudinal mixed model; data not shown; Figure 2). As with LPS,
increased sCD14 levels in HIV-infected infants, compared with
uninfected infants, were evident at birth (Table 1).
In contrast, there was no significant difference in sL-selectin
levels between HIV-infected infants and uninfected infants
except at the time of birth (Table 1 and Figure 3). At birth,
HIV-infected infants (most of whom had in utero–acquired
infections) had higher levels of lymphocyte activation than
HIV-uninfected infants.
Levels of CD4+ and CD8+ T lymphocyte immune activation
were generally higher in HIV-infected infants, compared with
uninfected infants (Table 1). As expected, differences in activa-
tion levels between HIV-infected infants and uninfected infants
were more pronounced for CD8+ T lymphocytes, rather than
for CD4+ T lymphocytes, which are directly depleted by HIV
(Table 1).
Immune Activation Markers Show Poor Correlation With
Microbial Translocation
Levels of LPS and sCD14 from birth to 48 weeks of age were
modestly (but statistically significantly) correlated in uninfected
infants (r = 0.33, P < .001) but not in HIV-infected infants
Table 1. Plasma Levels of Lipopolysaccharide (LPS), Soluble CD14 (sCD14), Soluble L-Selectin (sL-Selectin), and Cellular Activation
Markers in Infants, by Age and Human Immunodeficiency Virus (HIV) Status at Study Visit
HIV Infected HIV Uninfected
Marker, Infant Age No. Median (IQR) No. Median (IQR) P
LPS level, EU/mL
Delivery 28 1.73 (1.41–2.17) 58 1.20 (0.41–1.68) .006
6 wk 4 1.56 (1.26–1.65) 43 1.20 (0.33–1.80) .446
24 wk 11 1.61 (1.30–2.92) 36 1.13 (0.21–2.01) .149
36 wk 7 1.84 (1.59–3.04) 38 1.60 (0.77–2.05) .107
48 wk 12 2.33 (1.66–3.11) 11 1.57 (0.56–2.08) .042
sCD14 level, ng/mL
Delivery 28 793 (725–935) 58 634 (501–813) .004
6 wk 4 1210 (1154–1447) 43 1190 (966.8–1391) .457
24 wk 11 1841 (1288–2314) 36 1393 (1123–1606) .046
36 wk 7 2323 (1862–2536) 38 1477 (1245–1875) .010
48 wk 12 2107 (1910–2656) 11 1410 (989.4–1859) .004
sL-selectin level, ng/mL
Delivery 28 882 (726–971) 58 684 (635–762) < .001
6 wk 4 1273 (841.2–1508) 43 1395 (1224–1719) .294
24 wk 11 2267 (1936–2591) 36 1981 (1754–2235) .081
36 wk 7 2235 (1977–2850) 38 2152 (1925–2426) .266
48 wk 12 2313 (2021–2736) 11 2213 (2074–2563) .735
% CD4+CD38+HLA-DR+
Delivery 28 0.70 (0.35–1.30) 64 0.30 (0.20–0.50) < .001
6 wk 4 4.55 (3.15–7.75) 44 0.95 (0.55–2.65) .023
24 wk 13 2.20 (1.00–3.30) 37 1.00 (0.60–2.00) .065
36 wk 9 3.00 (1.90–3.20) 36 2.00 (1.00–3.30) .326
48 wk 12 3.40 (2.15–5.15) 11 3.00 (0.80–3.40) .241
% CD8+CD38+HLA-DR+
Delivery 27 6.40 (2.20–16.0) 55 0.50 (0.20–0.80) <.001
6 wk 4 23.0 (17.6–28.4) 37 7.00 (2.00–12.8) .012
24 wk 13 14.1 (12.0–21.0) 29 6.00 (2.00–13.0) .018
36 wk 7 16.0 (6.80–18.0) 31 11.0 (4.00–15.0) .187
48 wk 12 15.2 (12.4–17.5) 11 4.60 (3.20–12.7) .029
Abbreviations: EU, enzyme units; IQR, interquartile range.
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(r = 0.21, P = .107). Plasma LPS levels were not significantly
correlated with sL-selectin levels in either HIV-infected infants
(r = 0.21) or uninfected infants (r = 0.08).
LPS levels were modestly (but significantly) correlated with
CD4+ T-lymphocyte immune activation in HIV-infected
infants (r = 0.27, P = .04) but not in HIV-uninfected infants
(r = 0.05, P = .47). There was no correlation between LPS and
CD8+ T lymphocyte immune activation (r = 0.08 for HIV-
uninfected infants, and r = 0.02 for HIV-infected infants).
Microbial Translocation Is Associated With HIV Transmission
Through Breast-feeding, Infant Cotrimoxazole Prophylaxis, and
Less Infant Growth
The preinfection plasma LPS level was a significant predictor of
infant HIV infection through breast-feeding (hazard ratio = 1.60
for every 1 unit increase in plasma LPS level; P = .01, adjusted
for study arm, maternal CD4+ T-cell count, and birth weight).
Plasma levels of sCD14 or sL-selectin, on the other hand, were
not significant predictors of infant HIV acquisition through
breast-feeding. Receipt of cotrimoxazole prophylaxis by infants
was a strong predictor of higher levels of plasma LPS (P = .004)
and sCD14 (P < .001) in a linear regression model, after adjust-
ment for maternal CD4+ T-cell count and infant birth weight.
This association remained after removing data collected after
36 weeks of age from the model, when cotrimoxazole prophy-
laxis was stopped for HIV-uninfected infants. Plasma LPS
levels were inversely associated with infant weight-for-age
(P = .191) and length-for-age (P = .002) z scores, after adjust-
ment for study arm, time, birth weight, maternal CD4+ T-cell
count, and infant sex and HIV status. Each 1.0-EU/mL increase
in LPS was significantly associated with a 0.05 decrease in
weight-for-age z score and a 0.17 decrease in length-for-age z
score. This equates to average decreases of 0.02 kg and 0.31 cm
at birth and 0.06 kg and 0.41 cm by 1 year of age per 1.0-EU/
mL increase in LPS level.
DISCUSSION
Our findings indicate that microbial translocation, as measured
by plasma LPS levels, increased after the infants’ first 6 months
of life, which coincided with weaning from breast milk for
HIV-uninfected infants in the study. Specifically, increases in
plasma LPS levels were observed in the weeks that followed
weaning (which occurred between 24 and 28 weeks of age), and
levels seemed to stabilize by 48 weeks of life in uninfected
infants. This pattern of postweaning increases in levels of mi-
crobial translocation temporally coincided with an increase in
Figure 1. Plasma bacterial lipopolysaccharide (LPS) levels, a marker of microbial translocation through the intestine, by infant age and human immuno-
deficiency virus (HIV) status at the particular BAN study visit. The median level at each study visit is indicated by a horizontal line, and the curves are esti-
mated using nonparametric smoothing splines.
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episodes of diarrhea that was previously reported in weaned
infants in the BAN study [14]. Previous studies indicated that
microbial translocation can be detected in healthy infants and
young children but decreases after 2 years of age in healthy chil-
dren [18]. To our knowledge, the impact of breast-feeding and
weaning on LPS levels has not been reported. Our finding sug-
gests that breast-feeding protects against disruption of the in-
testinal mucosal barrier or that artificial or formula feeding
may stimulate gut inflammation. Breast milk contains a multi-
tude of factors, such as lactoferrin or transforming growth
factor β, with growth-promoting properties for the gut that
help maintain the integrity of the epithelial barrier and may
thus prevent microbial translocation [2, 19].
Plasma LPS levels in infants in this study were lower, compared
with levels in those from a study of formula-fed infants [12]. Pres-
ence of LPS in infant formula or in the water used to dilute
formula has been postulated as a reason to account for the early
detection of LPS in formula-fed infants [12]. Plasma LPS levels
in our study were comparable with those found in HIV-unin-
fected adults and children from Africa [18].
Compared with uninfected infants, HIV-infected infants had
higher levels of microbial translocation at birth and at 48 weeks
of life. Increased LPS levels have been observed in infants [12, 18],
adults [20], and children [18, 21, 22] with HIV infection. This
could be either the cause or the effect, or both, of HIV infec-
tion. It is now recognized that acute HIV infection causes de-
pletion of mucosal lymphocytes, particularly subsets such as
T-helper 17 cells in the gut, leading to disruption of the mucosal
immune system and microbial translocation [23]. In young
infants, the disruptions to the gut mucosa caused by HIV infec-
tion may be compounded by the physiologic immaturity of the
gut [18, 24, 25]. However, the fact that most cases of HIV infec-
tion through breast-feeding in our study were predicted by
prior increases in LPS, but not in immune activation markers,
suggests a causal role of disrupted mucosal integrity in such
transmission. A previous study did not find that increases in in-
testinal permeability measured by the lactulose-mannitol assay
explained which infants became HIV-infected via breast-
feeding [26]; however, assessments were made only in the first
14 weeks of life, and there were only 3 infants with confirmed
HIV infection via breast-feeding by 14 weeks in that study.
Differences in gut microbiota may also affect levels of micro-
bial translocation. This is supported by our finding that use of
antibiotic prophylaxis was a predictor of increased plasma LPS
levels, suggesting that disruption in the infants’ intestinal micro-
flora, caused by the chronic administration of a broad-spectrum
antibiotic, can lead to increased microbial translocation. Infant
milk source and complementary foods are also known to affect
Figure 2. Plasma soluble CD14 levels, a marker of monocyte/macrophage activity, by infant age and human immunodeficiency virus (HIV) status at the
particular BAN study visit. The median level at each study visit is indicated by a horizontal line, and the curves are estimated using nonparametric smooth-
ing splines.
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the composition of gut flora [27]. Taken together, the observa-
tions of increases in microbial translocation with chronic antibi-
otic prophylaxis and after weaning from breast milk suggest a
model in which disruption of the microbiota leads to increased
levels of mucosal injury and immune activation. To our knowl-
edge, this finding has not been previously reported. The use of
cotrimoxazole prophylaxis in HIV-infected infants and HIV-
exposed but uninfected infants has health benefits, as has been
demonstrated in BAN and other studies [28–30]. Probiotics
therapy or other approaches may need to be evaluated for their
ability to reverse such adverse effects of antibiotics [31].
Microbial translocation was also correlated with slower
infant linear growth in our study. This finding, to our knowl-
edge, has not been previously reported. However, it is consis-
tent with previous reports of association of increased intestinal
permeability with infant growth retardation in resource-limited
settings [5, 32, 33].
Microbial translocation is a force driving immune activa-
tion [9]. We found a modest correlation of plasma LPS levels
with monocyte activity (measured by plasma sCD14 levels) in
uninfected infants. However, LPS levels did not significantly
correlate with lymphocyte activation (measured by expression
of activation markers on CD4+ and CD8+ T lymphocytes and
plasma levels of sL-selectin). Lack of correlation of LPS levels
with lymphocyte activation markers has been reported in other
studies, as well [12, 18, 22]. None of the immune activation
markers was predictive of HIV transmission through breast-
feeding, supporting the hypothesis that breeches in gut mucosa
barrier are important for HIV transmission, rather than endo-
toxin-induced immune activation.
Our study has some limitations. HIV-uninfected infants
were weaned at 6 months of age; thus, we were unable to
compare the dynamics of LPS levels with those in correspond-
ing infants who continued to breast-feed throughout the first
year of life. Also, we did not have a control group of infants
who received formula from birth. Varying degrees of mixed
feeding likely occurred in our study cohort. The relatively small
sample size studied precluded evaluation of a direct correlation
of microbial translocation with gastrointestinal morbidity. All
infants in our study were born to HIV-infected mothers in a
resource-limited setting with a high background of endemic
diarrhea, which could affect the generalizability of the results.
In conclusion, our findings indicate that levels of microbial
translocation in infancy appear to increase with weaning from
breast milk and with chronic receipt of antibiotic prophylaxis.
Microbial translocation correlated modestly with monocyte
Figure 3. Plasma soluble L-selectin levels, a marker of lymphocyte activation, by infant age and human immunodeficiency virus (HIV) status at the par-
ticular BAN study visit. The median level at each study visit is indicated by a horizontal line, and the curves are estimated using nonparametric smoothing
splines.
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and not with lymphocyte immune activation in the infants; mi-
crobial translocation was associated with poorer infant growth.
Importantly, microbial translocation (but not immune activa-
tion) was a significant predictor of acquisition of HIV infection
through breast-feeding after adjustment for covariates, suggest-
ing that increased intestinal permeability may be one of the
mechanisms of HIV infection through breast-feeding. These
findings suggest that, in addition to antiretroviral prophylaxis,
complementary pathways to further reduce HIV transmission
through breast-feeding can be based on enhancing intestinal
mucosal integrity. Such approaches may include promotion of
more-prolonged breast-feeding and implementation of appropri-
ate interventions, including vaccination (eg, rotavirus vaccine),
hygiene-improvement activities (eg, water sanitation programs),
and, perhaps, supplementation with probiotic or other prepara-
tions for infants receiving antibiotics, to minimize gastrointesti-
nal infections.
Notes
Acknowledgments. We thank the BAN Study Team at the University of
North Carolina–Chapel Hill, the Centers for Disease Control and Preven-
tion, and UNC Project–Malawi, including Linda Adair, Yusuf Ahmed,
Mounir Ait-Khaled, Sandra Albrecht, Shrikant Bangdiwala, Ronald Bayer,
Margaret Bentley, Brian Bramson, Emily Bobrow, Nicola Boyle, Sal Butera,
Charles Chasela, Charity Chavula, Joseph Chimerang’ambe, Maggie Chig-
wenembe, Maria Chikasema, Norah Chikhungu, David Chilongozi, Grace
Chiudzu, Lenesi Chome, Anne Cole, Amanda Corbett, Amy Corneli, Anna
Dow, Ann Duerr, Henry Eliya, Sascha Ellington, Joseph Eron, Sherry Farr,
Yvonne Owens Ferguson, Susan Fiscus, Valerie Flax, Ali Fokar, Shannon
Galvin, Laura Guay, Chad Heilig, Irving Hoffman, Elizabeth Hooten, Mina
Hosseinipour, Michael Hudgens, Stacy Hurst, Lisa Hyde, Denise Jamieson,
George Joaki (deceased), David Jones, Elizabeth Jordan-Bell, Zebrone Ka-
cheche, Esmie Kamanga, Gift Kamanga, Coxcilly Kampani, Portia Kam-
thunzi, Deborah Kamwendo, Cecilia Kanyama, Angela Kashuba, Damson
Kathyola, Dumbani Kayira, Peter Kazembe, Caroline C. King, Rodney
Knight, Athena P. Kourtis, Robert Krysiak, Jacob Kumwenda, Hana Lee,
Edde Loeliger, Dustin Long, Misheck Luhanga, Victor Madhlopa, Magani-
zo Majawa, Alice Maida, Cheryl Marcus, Francis Martinson, Navdeep
Thoofer, Chrissie Matiki (deceased), Douglas Mayers, Isabel Mayuni,
Marita McDonough, Joyce Meme, Ceppie Merry, Khama Mita, Chim-
wemwe Mkomawanthu, Gertrude Mndala, Ibrahim Mndala, Agnes Moses,
Albans Msika, Wezi Msungama, Beatrice Mtimuni, Jane Muita, Noel
Mumba, Bonface Musis, Charles Mwansambo, Gerald Mwapasa, Jacqueline
Nkhoma, Megan Parker, Richard Pendame, Ellen Piwoz, Byron Raines,
Zane Ramdas, John Rublein, Mairin Ryan, Ian Sanne, Christopher Sellers,
Diane Shugars, Dorothy Sichali, Wendy Snowden, Alice Soko, Allison
Spensley, Jean-Marc Steens, Gerald Tegha, Martin Tembo, Roshan Thomas,
Hsiao-Chuan Tien, Beth Tohill, Charles van der Horst, Esther Waalberg,
Elizabeth Widen, Jeffrey Wiener, Cathy Wilfert, Patricia Wiyo, Innocent
Zgambo, and Chifundo Zimba; G. Xia, S. Ramachandran, and Y. Khudya-
kov, for facilitating the HBV sequencing; and the women and infants who
participated in the BAN study.
Disclaimer. The findings and conclusions in this paper are those of the
authors and do not necessarily represent the official position of the Centers
for Disease Control and Prevention.
Financial support. This work was supported by the Prevention Re-
search Centers Special Interest Project of the Centers for Disease Control
and Prevention (grants SIP 13-01 U48-CCU409660-09, SIP 26-04 U48-
DP000059-01, and SIP 22-09 U48-DP001944-01), the National Institute of
Allergy and Infectious Diseases, the University of North Carolina Center
for AIDS Research (grant P30-AI50410), the NIH Fogarty AIDS
International Training and Research Program (grants DHHS/NIH/FIC
2-D43 Tw01039-06 and R24 Tw00798; the American Recovery and Rein-
vestment Act), and the Emory University Center For AIDS Research Immu-
nology Core (grant P30A01050409). The antiretrovirals used in the BAN
study were donated by Abbott Laboratories, GlaxoSmithKline, Boehringer
Ingelheim, Roche Pharmaceuticals, and Bristol-Myers Squibb. The Call to
Action PMTCT program was supported by the Elizabeth Glaser Pediatric
AIDS Foundation, the United Nations Children’s Fund, the World Food
Program, the Malawi Ministry of Health and Population, Johnson &
Johnson, and the US Agency for International Development.
Potential conflicts of interest. All authors: No reported conflicts.
All authors have submitted the ICMJE Form for Disclosure of Potential
Conflicts of Interest. Conflicts that the editors consider relevant to the
content of the manuscript have been disclosed.
References
1. Kourtis AP, Butera S, Ibegbu C, et al. Breast milk and HIV-1: vector of
transmission or vehicle of protection? Lancet Infect Dis 2003; 3:
786–93.
2. Sherman MP. New concepts of microbial translocation in the neonatal
intestine: Mechanisms and Prevention. Clin Perinatol 2010; 37:565–79.
3. Catassi C, Bonucci A, Coppa G, et al. Intestinal permeability changes
during the first month: effect of natural versus artificial feeding. J
Pediatr Gastroenterol Nutr 1995; 21:383–6.
4. Coutsoudis A, Pillay K, Spooner E, Kuhn L, Coovadia HM. Influence of
infant feeding patterns on early mother to child transmission of HIV-1
in Durban, South Africa: a prospective cohort study. South African
Vitamin A Study Group. Lancet 1999; 354:471–6.
5. Lunn PG. The impact of infection and nutrition on gut function and
growth in childhood. Proceed Nutr Society 2000; 59:147–54.
6. Schietroma M, Carlei F, Cappelli S, Amicucci G. Intestinal permeability
and systemic endotoxemia after laparatomic or laparoscopic Cholecys-
tectomy. Ann Surg 2006; 243:359–63.
7. Suffredini AF, Hochstein HD, McMahon FG. Dose-related inflammato-
ry effects of intravenous endotoxin in humans: evaluation of a new clin-
ical lot of Escherichia coli O: 113 endotoxin. J Infect Dis 1999; 179:
1278–82.
8. Favre D, Ledere S, Kanwar B, et al. Critical loss of the balance between
Th17 and T regulatory cell populations in pathogenic SIV infection.
Plos Pathog 2009; e1000295.
9. Brenchley JM, Price DA, Schacker TW, et al. Microbial translocation is
a cause of systemic immune activation in chronic HIV infection. Nat
Med 2006; 12:1365–71.
10. Caradonna L, Amati L, Magrone T, et al. Enteric bacteria, lipopolysac-
charides and related cytokines in inflammatory bowel disease: biologi-
cal and clinical significance. J Endotoxin Res 2000; 6:205–14.
11. Cooke KR, Olkiewicz K, Erickson N, Ferrara JL. The role of endotoxin
and innate immune response in the pathophysiology of acute graft
versus host disease. J Endotoxin Res 2002; 8:441–8.
12. Papasavvas E, Azzoni L, Foulkes A, et al. Increased microbial transloca-
tion in less than 180 days old perinatally HIV-positive infants as com-
pared with HIV-exposed uninfected infants of similar age. Pediatr
Infect Dis J 2011; 30:877–82.
13. Van der Horst C, Chasela C, Ahmed Y, et al. Modifications of a large
HIV prevention clinical trial to fit changing realities: a case study of the
Breastfeeding, Antiretroviral, and Nutrition (BAN) protocol in Lilong-
we, Malawi. Contemp Clin Trials 2009; 30:24–33.
14. Jamieson DJ, Chasela CS, Hudgens MG, et al. Maternal and infant anti-
retroviral regimens to prevent postnatal HIV-1 transmission: 48 week
follow-up of the BAN randomized controlled trial. Lancet 2012; 379:
2449–58.
15. WHOMulticentre Growth Reference Study Group. WHO child growth
standards: length/height-for-age, weight-for-age, weight-for-length,
weight-for-height and body mass index-for-age: methods and develop-
ment. Geneva: World Health Organization, 2006.
660 • JID 2013:208 (15 August) • Kourtis et al
16. Bryson YJ, Luzuriaga K, Sullivan JL, et al. Proposed definitions for in
utero versus intrapartum transmission of HIV-1. N Engl J Med 1992;
327:1246–7.
17. Kourtis AP, Ibegbu CC, Theiler R, et al. Breast milk CD4+ T cells
express high levels of C chemokine receptor 5 and CXC chemokine re-
ceptor 4 and are preserved in HIV-infected mothers receiving highly
active antiretroviral therapy. J Infect Dis. 2007; 195:965–72.
18. Wallet MA, Rodriguez CA, Lin Y, et al. Microbial translocation induces
persistent macrophage activation unrelated to HIV-1 levels or T cell ac-
tivation following therapy. AIDS 2010; 24:1281–90.
19. Planchon SM, Martins CA, Guerrant RL, et al. Regulation of intestinal
epithelial barrier function. J Immunol 1994; 153:5370–9.
20. Cassol E, Malfeld S, Mahasha P, et al. Persistent microbial translocation
and immune activation in HIV-1-infected South Africans receiving
combination antiretroviral therapy. J Infect Dis 2010; 202:723–33.
21. Anselmi A, Vendrame D, Rampon O, Giaquinto C, Zanchetta M, De
Rossi A. Immune reconstitution in HIV type 1-infected children with
different virological responses to antiretroviral therapy. Clin Exp
Immunol 2007; 150:442–50.
22. Pilakka-Kanthikeel S, Huang S, Fenton T, Borkowsky W, Cunningham
CKPahwa S. Increased gut microbial translocation in HIV-infected
children persists in virologic responders and virologic failures after an-
tiretroviral therapy. Pediatr Infect Dis J 2012; 31:583–91.
23. Brenchley JM, Paiardini M, Knox KS, et al. Differential Th17 CD4 T-
cell depletion in pathogenic and nonpathogenic lentiviral infections.
Blood 2008; 112:2826–35.
24. Quing G, Howlett S, Bortolussi R. Lipopolysaccharide binding proteins
on polymorphonuclear leucocytes: comparison of adult and neonatal
cells. Infect Immun 1996; 64:4638–42.
25. Wold A, Adlerberth I. Breastfeeding and the intestinal microflora of the
infant-implications for protection against infectious diseases. Adv Exp
Med Biol 2000; 478:77–93.
26. Rollins NC, Filteau SM, Coutsoudis A, Tomkin AM. Feeding mode, in-
testinal permeability, and neopterin excretion: a longitudinal study in
infants of HIV-infected South African women. J Acquir Immune Defic
Syndr 2001; 28:132–9.
27. Nielsen S, Nielsen DS, Lauritzen L, Jakobsen M, Michaelson K. Impact
of diet on the intestinal microbiota in 10-month-old infants. J Pediatr
Gastroenterol Nutr 2007; 44:613–8.
28. Kourtis AP, Wiener J, Kayira D, et al. Health outcomes of HIV-exposed
uninfected African infants. AIDS 2013; 27:749–59.
29. Taha TE, Hoover DR, Chen S, et al. Effects of cessation of breastfeeding
in HIV-1-exposed, uninfected children in Malawi. Clin Infect Dis
2011; 53:388–95.
30. Mulenga V, Ford D, Walker AS, et al. Effect of cotrimoxazole on causes
of death, hospital admissions and antibiotic use in HIV-infected chil-
dren. AIDS 2007; 21:77–84.
31. Cunningham-Rundles S, Ahrne S, Johann-Liang R, et al. Effect of pro-
biotic bacteria on microbial host defense, growth, and immune function
in human immunodeficiency virus type-1 infection. Nutrients 2011;
3:1042–70.
32. Campbell DI, Elia M, Lunn PG. Growth faltering in rural Gambian
infants is associated with impaired small intestinal barrier function,
leading to endotoxemia and systemic inflammation. J Nutr 2003; 133:
1332–8.
33. Lunn PG, Northrop-Clewes CA, Downes RM. Intestinal permeability,
mucosal injurty, and growth faltering in Gambian infants. Lancet 1991;
338:907–10.
Intestinal Integrity and HIV Transmission via Breast-feeding • JID 2013:208 (15 August) • 661
